Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?

Critical Reviews in Oncology/Hematology

Volumn 105, Issue , 2016, Pages 5-17

  Rizzieri, David ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Ibritumomab tiuxetan; Non Hodgkin's lymphoma; Radioimmunotherapy; Zevalin

Indexed keywords

IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY;

ACUTE MYELOID LEUKEMIA; AGE; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DIFFUSE LARGE B CELL LYMPHOMA; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFUSION RELATED REACTION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; QUALITY OF LIFE; REVIEW; SECOND CANCER; SIDE EFFECT; THROMBOCYTOPENIA; ANIMAL; B LYMPHOCYTE; DISEASE COURSE; DRUG EFFECTS; HUMAN; LYMPHOMA, NON-HODGKIN; RISK FACTOR;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; DISEASE PROGRESSION; HUMANS; LYMPHOMA, NON-HODGKIN; RISK FACTORS;

EID: 85016416798     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.07.008     Document Type: Review

References (86)

1. American Cancer Society, American Cancer Society: Cancer Facts & Figs. 2015 (accessed 14.10.15) http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
2. Andrade-Campos, M.M., Montes-Limón, A.E., Soro-Alcubierre, G., et al. Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life. Ann. Hematol. 93 (2014), 1985–1992.
3. Andrade-Campos, M.M., Montes-Limón, A.E., Soro-Alcubierre, G., et al. Patients older than 65 years with non-Hodgkin lymphoma are suitable for treatment with (90)Yttrium-ibritumumab tiuxetan: a single institution experience. Clin. Lymphoma Myeloma Leuk. 15 (2015), 464–471.
4. Armitage, J.O., Carbone, P.P., Connors, J.M., et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J. Clin. Oncol. 21 (2003), 897–906.
5. Berinstein, N.L., Bhella, S., Pennell, N.M., et al. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab. Ann. Hematol. 94 (2015), 813–823.
6. Bethge, W.A., Lange, T., Meisner, C., et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood 116 (2010), 1795–1802.
7. Briones, J., Novelli, S., García-Marco, J.A., et al. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica 99 (2014), 505–510.
8. Brugger, W., Ghielmini, M., Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. Oncologist 18 (2013), 954–964.
9. Campo, E., Swerdlow, S.H., Harris, N.L., et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117 (2011), 5019–5032.
10. Chamarthy, M.R., Williams, S.C., Moadel, R.M., Radioimmunotherapy of non-Hodgkin's lymphoma: from the magic bullets to radioactive magic bullets. Yale J. Biol. Med. 84 (2011), 391–407.
11. Chan, J.K., The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol. Oncol. 19 (2001), 129–150.
12. Chen, Q., Ayer, T., Nastoupil, L.J., et al. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health 18 (2015), 189–197.
13. Chinn, P.C., Leonard, J.E., Rosenberg, J., et al. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int. J. Oncol. 15 (1999), 1017–1025.
14. Chu, P.G., Loera, S., Huang, Q., et al. Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study. Am. J. Clin. Pathol. 126 (2006), 534–544.
15. Czuczman, M.S., Emmanouilides, C., Darif, M., et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J. Clin. Oncol. 25 (2007), 4285–4292.
16. Czuczman, M.S., Emmanouilides, C., Darif, M., et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J. Clin. Oncol. 25 (2007), 4285–4292.
17. DeNardo, G.L., Concepts in radioimmunotherapy and immunotherapy: radioimmunotherapy from a Lym-1 perspective. Semin. Oncol. 32 (2005), S27–S35.
18. Devizzi, L., Guidetti, A., Tarella, C., et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J. Clin. Oncol. 26 (2008), 5175–5182.
19. 90Y-ibritumomab tiuxetan for patients with poor-risk non-Hodgkin lymphoma not eligible for high-dose BEAM. J. Clin. Oncol. 31 (2013), 2974–2976.
20. Dixon, K.L., The radiation biology of radioimmunotherapy. Nucl. Med. Commun. 24 (2003), 951–957.
21. Dreyling, M., Ghielmini, M., Marcus, R., et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (2014), iii76–iii82.
22. Emmanouilides, C., Radioimmunotherapy for non-hodgkin lymphoma: historical perspective and current status. J. Clin. Exp. Hematop. 47:2 (2007), 43–60.
23. Flinn, I.W., Van der Jagt, R.H., Kahl, B.S., et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): the Bright Study. 54th Annual Meeting of the American Society of Hematology, December 8–11, 2012; Atlanta, GA, 2016 (Abstract 902).
24. Freedman, A.S., Nadler, L.M., Pathology, immunobiology, and natural history of NHL. Holland-Frei Cancer Medicine, 6th ed., 2003, BC Decker, Hamilton, ON (accessed 09.11.15) http://www.ncbi.nlm.nih.gov/books/NBK13723/.
25. Garber, K., Users fear that lymphoma drugs will disappear. J. Natl. Cancer Inst. 99 (2007), 498–499 (501).
26. 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 118 (2011), 1132–1139.
27. Gordon, L.I., Witzig, T., Molina, A., et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma 5 (2004), 98–101.
28. Gordon, L.I., Molina, A., Witzig, T., et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103 (2004), 4429–4431.
29. Guidetti, A., Carlo-Stella, C., Ruella, M., et al. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. Cancer 117 (2011), 5074–5084.
30. Hermet, E., Cabrespine, A., Guieze, R., et al. Autologous hematopoietic stem cell transplantation in elderly patients (≥70 years) with non-Hodgkin's lymphoma: a French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study. J. Geriatr. Oncol. 6 (2015), 346–352.
31. Hitt, E., FDA Removes Ibritumomab Bioscan Requirement. 2011 (accessed 09.11.15) http://www.medscape.com/viewarticle/753947.
32. Hochster, H., Weller, E., Gascoyne, R.D., et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG 1496 Study. J. Clin. Oncol. 27 (2009), 1607–1614.
33. Hohloch, K., Lankeit, H.K., Zinzani, P.L., et al. Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. Eur. J. Nucl. Med. Mol. Imaging 41 (2014), 1585–1592.
34. 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J. Clin. Oncol. 32 (2014), 212–218.
35. Illidge, T.M., Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date. J. Clin. Oncol. 28 (2010), 2944–2946.
36. Inwards, D.J., Cilley, J.C., Winter, J.N., Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma. Best Pract. Res. Clin. Haematol. 19 (2006), 669–684.
37. Jaffe, E.S., The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematol. Am. Soc. Hematol. Educ. Program 52 (2009), 3–531.
38. Johnson, P.W., Rohatiner, A.Z., Whelan, J.S., et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J. Clin. Oncol. 13 (1995), 140–147.
39. Josting, A., Sieniawski, M., Glossmann, J.P., et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann. Oncol. 16 (2005), 1359–1365.
40. Kimball, A.S., Webb, T.J., The roles of radiotherapy and immunotherapy for the treatment of lymphoma. Mol. Cell Pharmacol. 5 (2013), 27–38.
41. Krishnan, A., Palmer, J.M., Tsai, N.C., et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy-versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol. Blood Marrow Transplant. 18 (2012), 441–450.
42. Lansigan, F., Zaki, B.I., Yen, S.P., et al. Short course of bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan in patients with chemotherapy-naive follicular lymphoma: results of Fol-Brite. 56th Annual Meeting of the American Society of Hematology, December 6–9, 2014; San Francisco, CA, 2016 (Abstract 1733).
43. Ma, D., McDevitt, M.R., Barendswaard, E., et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 16 (2002), 60–66.
44. Martin, N., Borchiellini, D., Coso, D., et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk. Lymphoma 56 (2015), 2379–2387.
45. Matesan, M., Rajendran, J., Press, O.W., et al. 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution. Nucl. Med. Commun. 35 (2014), 1132–1142.
46. Mei, M., Wondergem, M.J., Palmer, J.M., et al. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. Biol. Blood Marrow Transplant. 20 (2014), 2072–2075.
47. Molina, A., Krishnan, A., Fung, H., et al. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90ibritumomab tiuxetan. Curr. Stem Cell Res. Ther. 2 (2007), 239–248.
48. Morschhauser, F., Radford, J., Van Hoof, A., et al. Phase III. trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 26 (2008), 5156–5164.
49. Morschhauser, F., Radford, J., Van Hoof, A., et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line lndolent trial. J. Clin. Oncol. 31 (2013), 1977–1983.
50. NCCN, National Cancer Institute: NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. 2015 (accessed 14.10.15) http://nccn.org.
51. Nademanee, A., Forman, S., Molina, A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 (2005), 2896–2902.
52. National Institute of Health, Combination Chemotherapy or 90-yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients with Relapsed Diffuse Large ß-cell Non-Hodgkin Lymphoma (SPINOZA). 2015, City of Hope Medical Center (accessed 09.10.15) https://clinicaltrials.gov/ct2/show/NCT02366663.
53. National Institute of Health, Zevalin Before Stem Cell Transplant in Treating Patients with Non-Hodgkin Lymphoma. 2016, University of California, Davis (accessed 09.10.15) https://clinicaltrials.gov/ct2/show/NCT01811368.
54. National Institute of Health, Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients with Relapsed Aggressive B-Cell NHL. 2016, University of Arizona (accessed 09.10.15) https://clinicaltrials.gov/ct2/show/NCT01686165.
55. Otte, A., Thompson, S.L., Practical and clinical benefits of radioimmunotherapy lead to advantages in cost-effectiveness in the treatment of patients with non-Hodgkin's lymphoma. Nucl. Med. Commun. 27 (2006), 753–756.
56. Philip, T., Guglielmi, C., Hagenbeek, A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 333 (1995), 1540–1545.
57. Pileri, S.A., Ascani, S., Sabattini, E., et al. The pathologist's view point: part I—indolent lymphomas. Haematologica 85 (2000), 1291–1307.
58. Press, O.W., Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas. J. Clin. Oncol. 26 (2008), 5147–5150.
59. Rajguru, S., Kristinsdottir, T., Eickhoff, J., et al. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high–tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Clin. Adv. Hematol. Oncol. 12 (2014), 509–515.
60. Read, E.D., Eu, P., Little, P.J., et al. The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma. Target Oncol. 10 (2015), 15–26.
61. Rummel, M.J., Niederle, N., Maschmeyer, G., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381 (2013), 1203–1210.
62. SEER Cancer Statistics Factsheets, SEER Cancer Statistics Factsheets: Non-Hodgkin Lymphoma. 2016, National Cancer Institute, Bethesda, MD Available at: http://seer.cancer.gov/statfacts/html/nhl.html.
63. Salles, G., Seymour, J.F., Offner, F., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377 (2011), 42–51.
64. Schaefer, N.G., Ma, J., Huang, P., et al. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U: S. medical oncologists and hematologists. J. Nucl. Med. 51 (2010), 987–994.
65. Schaefer, N.G., Huang, P., Buchanan, J.W., et al. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J. Nucl. Med. 52 (2011), 830–838.
66. Scholz, C.W., Pinto, A., Linkesch, W., et al. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J. Clin. Oncol. 31 (2013), 308–313.
67. Shimoni, A., Zwas, S.T., Oksman, Y., et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp. Hematol. 35 (2007), 534–540.
68. Shimoni, A., Zwas, S.T., Oksman, Y., et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant. 41 (2008), 355–361.
69. Shimoni, A., Avivi, I., Rowe, J.M., et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 118 (2012), 4706–4714.
70. Siddiqi, T., Tsai, N.-C., Palmer, J.M., et al. Effect of radioimmunotherapy-based poor-risk molecular profiling in diffuse large B-cell lymphoma. J. Clin. Oncol., 3, 2012, 0 (Abstract 6547).
71. Wagner, H.N. Jr., Wiseman, G.A., Marcus, C.S., Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J. Nucl. Med. 43 (2002), 267–272.
72. Waterman, J., Rybicki, L., Bolwell, B., et al. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 47 (2012), 488–493.
73. Wiseman, G.A., White, C.A., Stabin, M., et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur. J. Nucl. Med. 27 (2000), 766–777.
74. Wiseman, G.A., Leigh, B., Witzig, T., et al. Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur. J. Nucl. Med., 28, 2001, 1198.
75. Wiseman, G.A., Gordon, L.I., Multani, P.S., et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99 (2002), 4336–4342.
76. Wiseman, G.A., Leigh, B., Erwin, W.D., et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94 (2002), 1349–1357.
77. Witzig, T.E., White, C.A., Wiseman, G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17 (1999), 3793–3803.
78. Witzig, T.E., Gordon, L.I., Cabanillas, F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20 (2002), 2453–2463.
79. Witzig, T.E., Flinn, I.W., Gordon, L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20 (2002), 3262–3269.
80. Witzig, T.E., White, C.A., Gordon, L.I., et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J. Clin. Oncol. 21 (2003), 1263–1270.
81. Witzig, T.E., Hong, F., Micallef, I.N., et al. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. Br. J. Haematol. 170 (2015), 679–686.
82. Witzig, T.E., Zevalin™. Drugs Future 27 (2002), 563–568.
83. 90Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation. Br. J. Haematol. 157 (2012), 395–397.
84. Zevalin, package Insert]. 2013, Spectrum Pharmaceuticals, Inc., Henderson, NV.
85. Zhang, M.M., Gopal, A.K., Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin. Hematol. 45 (2008), 118––125.
86. Zhu, X., Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin. Nucl. Med. 34 (2004), 20–23.